Presentation:  4:00-5:00PM
Discussion & Reception: 5:00-6:00PM

Representative from Biogen Idec:
David R. Parkinson, MD, Senior Vice President, Oncology Research and Development

Topics/Compounds to be presented:

• Rituximab  
• Galiximab -  anti CD 80
• Anti-CD23  -  lumiliximab
• Anti-alpha5 beta 1: volociximab
• HSP90 inhibitors: BIIB021 and BIIB028
• anti-CRYPTO immunoconjugate

Note: Presentations are designated for DF/HCC members only and are not open to the public.

For more information, please contact Petra Loesch at 617-724-3867 or ploesch@partners.org.